These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29085971)

  • 21. [New institute for additional drug evaluation. Do we really need another barrier?].
    Schmidt K
    MMW Fortschr Med; 2003 Jul; 145(29-30):55-6. PubMed ID: 12958781
    [No Abstract]   [Full Text] [Related]  

  • 22. [Limited prescribing freedom by federal cost regulation?].
    Lasek R
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anthroposophic treatment in pediatrics--a critical analysis].
    Burkhard B
    Versicherungsmedizin; 2004 Dec; 56(4):197-9. PubMed ID: 15633774
    [No Abstract]   [Full Text] [Related]  

  • 24. [Vascular specialists in a campaign against positive list. Threat of deficient care for 4.5 million vascular patients].
    Krankenpfl J; 2003; 41(4-6):120. PubMed ID: 12929329
    [No Abstract]   [Full Text] [Related]  

  • 25. [Solutions for off-label therapy].
    Schmidt WA
    Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ["Off-label use" of botulinum toxin preparations in treatment of spasmodic dysphonia. Position of the German Society of Phoniatrics and Pediatric Audiology].
    Ptok M; Schönweiler R; Nawka T;
    HNO; 2004 Jan; 52(1):45-9. PubMed ID: 14740114
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
    MMW Fortschr Med; 2008 Aug; 150(32-35):56-7. PubMed ID: 19009700
    [No Abstract]   [Full Text] [Related]  

  • 28. [MSD executive calls for more transparency and expertise. 9 out of 10 innovations fail due to a too brief value assessment (interview by Wolfgang van den Bergh, Dirk Einecke and Cornelius Heyer)].
    Quodt H
    MMW Fortschr Med; 2011 Jan; 153(4):10. PubMed ID: 22165606
    [No Abstract]   [Full Text] [Related]  

  • 29. [The pediatric drug initiative].
    Krankenpfl J; 2005; 43(7-10):218-9. PubMed ID: 16515290
    [No Abstract]   [Full Text] [Related]  

  • 30. [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?].
    Schwarz S; Frölich L; Striebel JP; Hennerici MG
    Dtsch Med Wochenschr; 2007 Jan; 132(3):108-12. PubMed ID: 17219346
    [No Abstract]   [Full Text] [Related]  

  • 31. [Off-label use of drugs--the legal framework].
    Koyuncu A
    Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
    [No Abstract]   [Full Text] [Related]  

  • 32. [Legal boundaries of negative and positive lists].
    Arndt M
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):630-2. PubMed ID: 9527457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacist can no longer substitute all medications].
    Zimmermann GW
    MMW Fortschr Med; 2014 Nov; 156 Spec no 2():10. PubMed ID: 25551996
    [No Abstract]   [Full Text] [Related]  

  • 34. [Not Available].
    Rofo; 2018 Feb; 190(2):197. PubMed ID: 29346822
    [No Abstract]   [Full Text] [Related]  

  • 35. [Health services research: essential for allocation decisions - joint statement].
    Pfaff H; Abholz H; Glaeske G; Icks A; Klinkhammer-Schalke M; Nellessen-Martens G; Neugebauer EA; Ohmann C; Schrappe M; Selbmann HK; Stemmer R;
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2496-500. PubMed ID: 21993809
    [No Abstract]   [Full Text] [Related]  

  • 36. [Negative lists and positive lists--health policy aspects].
    Huber E
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):624-7. PubMed ID: 9527455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New developments also in general medicine. GSK relies on research as well as transparent collaboration with physicians (interview by Dirk Einecke, Wolfgang van den Bergh, Peter Overbeck and Cornelius Heyer)].
    Marshall CG; Strohmeyer T
    MMW Fortschr Med; 2011 May; 153(21):10-1. PubMed ID: 21739676
    [No Abstract]   [Full Text] [Related]  

  • 38. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 39. [Off-label therapy in rheumatology].
    Krüger K; Sieper J
    Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
    [No Abstract]   [Full Text] [Related]  

  • 40. India tries to improve national system for handling clinical trials.
    Sharma DC
    Lancet; 2001 May; 357(9269):1682. PubMed ID: 11425387
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.